Skip to main content

Antiemetics: American Society of Clinical Oncology Focused Guideline Update.

Publication ,  Journal Article
Hesketh, PJ; Bohlke, K; Lyman, GH; Basch, E; Chesney, M; Clark-Snow, RA; Danso, MA; Jordan, K; Somerfield, MR; Kris, MG ...
Published in: J Clin Oncol
February 1, 2016

PURPOSE: To update a key recommendation of the American Society of Clinical Oncology antiemetic guideline. This update addresses the use of the oral combination of netupitant (a neurokinin 1 [NK1] receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for the prevention of acute and delayed nausea and vomiting in patients receiving chemotherapy. METHODS: An update committee conducted a targeted systematic literature review and identified two phase III clinical trials and a randomized phase II dose-ranging study. RESULTS: In one phase III trial, the oral combination of netupitant and palonosetron was associated with higher complete response rates (no emesis and no rescue medications) compared with palonosetron alone in patients treated with anthracycline plus cyclophosphamide chemotherapy (74% v 67% overall; P = .001). In another phase III trial, the oral combination of netupitant and palonosetron was safe and effective across multiple cycles of moderately or highly emetogenic chemotherapies. In the phase II dose-ranging study, each dose of netupitant (coadministered with palonosetron 0.50 mg) produced higher complete response rates than palonosetron alone among patients receiving cisplatin-based chemotherapy. The highest dose of netupitant (ie, 300 mg) was most effective. RECOMMENDATIONS: All patients who receive highly emetogenic chemotherapy regimens (including anthracycline plus cyclophosphamide) should be offered a three-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone. The oral combination of netupitant and palonosetron plus dexamethasone is an additional treatment option in this setting. The remaining recommendations from the 2011 ASCO guideline are unchanged pending a full update. Additional information is available at www.asco.org/guidelines/antiemetics and www.asco.org/guidelineswiki.

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 1, 2016

Volume

34

Issue

4

Start / End Page

381 / 386

Location

United States

Related Subject Headings

  • Vomiting
  • Randomized Controlled Trials as Topic
  • Oncology & Carcinogenesis
  • Nausea
  • Humans
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic
  • Antineoplastic Combined Chemotherapy Protocols
  • Antiemetics
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hesketh, P. J., Bohlke, K., Lyman, G. H., Basch, E., Chesney, M., Clark-Snow, R. A., … American Society of Clinical Oncology. (2016). Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol, 34(4), 381–386. https://doi.org/10.1200/JCO.2015.64.3635
Hesketh, Paul J., Kari Bohlke, Gary H. Lyman, Ethan Basch, Maurice Chesney, Rebecca Anne Clark-Snow, Michael A. Danso, et al. “Antiemetics: American Society of Clinical Oncology Focused Guideline Update.J Clin Oncol 34, no. 4 (February 1, 2016): 381–86. https://doi.org/10.1200/JCO.2015.64.3635.
Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016 Feb 1;34(4):381–6.
Hesketh, Paul J., et al. “Antiemetics: American Society of Clinical Oncology Focused Guideline Update.J Clin Oncol, vol. 34, no. 4, Feb. 2016, pp. 381–86. Pubmed, doi:10.1200/JCO.2015.64.3635.
Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016 Feb 1;34(4):381–386.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 1, 2016

Volume

34

Issue

4

Start / End Page

381 / 386

Location

United States

Related Subject Headings

  • Vomiting
  • Randomized Controlled Trials as Topic
  • Oncology & Carcinogenesis
  • Nausea
  • Humans
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic
  • Antineoplastic Combined Chemotherapy Protocols
  • Antiemetics
  • 3211 Oncology and carcinogenesis